Dr. Reddy’s Q1 FY17 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Jefferies Downgrades Dr. Reddy's Laboratories (RDY) to Underperform
July 27, 2016 8:49 AM EDTJefferies downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Hold to Underperform with a price target of $41.90 (from $45.00).
Analyst Piyush Nahar commented, "DRRD results confirmed our fears of a sharp earnings hit for Indian generics given the increased pricing pressure and concentrated portfolio... More
